Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.44 |
| ▸ | AKT1 | P31749 | 10/20 | 0.42 |
| ▸ | AKT2 | P31751 | 10/20 | 0.42 |
| ▸ | AKT3 | Q9Y243 | 10/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL191660 | 1.00 | KIT (0.44) | KITAKT1AKT2AKT3GPR119 | |
| SCHEMBL29822476 | 1.00 | KIT (0.44) | KITAKT1AKT2AKT3GPR119 | |
| SCHEMBL2261991 | 1.00 | KIT (0.44) | KITAKT1AKT2AKT3GPR119 | |
| SCHEMBL191634 | 1.00 | KIT (0.44) | KITAKT1AKT2AKT3GPR119 | |
| SCHEMBL193005 | 1.00 | KIT (0.44) | KITAKT1AKT2AKT3GPR119 | |
| SCHEMBL25279204 | 0.91 | KIT (0.43) | KITAKT1AKT2AKT3GPR119 | |
| SCHEMBL925431 | 0.90 | KIT (0.46) | KITAKT1AKT2AKT3GPR119 | |
| SCHEMBL21506838 | 0.90 | KIT (0.46) | KITAKT1AKT2AKT3GPR119 | |
| SCHEMBL193356 | 0.86 | GPR119 (0.43) | KITAKT1AKT2AKT3GPR119 | |
| SCHEMBL193220 | 0.86 | GPR119 (0.43) | KITAKT1AKT2AKT3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152588-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2025-05-15 | — | — | US | disclosed |
| US-20220226326-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2022-07-21 | — | — | US | disclosed |
| CN-112915092-A | Combinations of AKT inhibitor compounds and abiraterone and methods of use | 基因泰克公司 | 2021-06-08 | — | — | CN | disclosed |
| US-20200345735-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-11-05 | — | — | US | disclosed |
| US-20200345735-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-11-05 | — | — | US | disclosed |
| CN-111643504-A | Combinations of AKT inhibitor compounds and chemotherapeutic agents and methods of use | 基因泰克公司 | 2020-09-11 | — | — | CN | disclosed |
| EP-3617330-A1 | BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS | Genentech, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| EP-2959014-B1 | METHODS AND COMPOSITIONS FOR DETECTING AND TREATING DRUG RESISTANT AKT MUTANT | GENENTECH INC (US) | 2019-11-13 | — | — | EP | disclosed |
| US-10092567-B2 | Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use | GENENTECH, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| EP-2694073-B1 | COMBINATIONS OF AKT AND MEK INHIBITORS FOR TREATING CANCER | GENENTECH INC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-2049501-A1 | HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-2049500-A1 | CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2009006567-A2 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20080058327-A1 | 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer | GENENTECH, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2008006040-A1 | HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008006040-A1 | HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008006032-A1 | CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058327-A1 | 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer | PIK3CA, DPYD, CDK2 | KIT 2033/4885AKT1 33/4885AKT2 23/4885 |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | KIT 1474/4885AKT1 1/4885AKT2 2/4885 |
| US-20220226326-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | KIT 1474/4885AKT1 1/4885AKT2 2/4885 |
| US-10092567-B2 | Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use | AKT1, AKT2, MTOR | KIT 483/4885AKT1 1/4885AKT2 2/4885 |
| US-20250152588-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | KIT 1474/4885AKT1 1/4885AKT2 2/4885 |
| US-20200345735-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | KIT 1474/4885AKT1 1/4885AKT2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.